Cellosaurus logo
expasy logo

Cellosaurus MDA-MB-468rDOX50 (CVCL_D6VR)

[Text version]
Cell line name MDA-MB-468rDOX50
Synonyms MDA-MB-468 rDoxorubicin50
Accession CVCL_D6VR
Resource Identification Initiative To cite this cell line use: MDA-MB-468rDOX50 (RRID:CVCL_D6VR)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Population: African American.
Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
  • Mutation; HGNC; 9588; PTEN; Simple; c.253+1G>T; ClinVar=VCV000189475; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line).
  • Mutation; HGNC; 9884; RB1; Simple; c.265_2787del2523; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
Disease Breast adenocarcinoma (NCIt: C5214)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0419 (MDA-MB-468)
Sex of cell Female
Age at sampling 51Y
Category Cancer cell line
Publications

DOI=10.1101/2024.01.20.576412
Grimsley H.E., Antczak M., McLaughlin K.-M., Nist A., Mernberger M., Stiewe T., Speidel D., Cox K., Cinatl J. Jr., Wass M.N., Garrett M.D., Michaelis M.
Resistance patterns in drug-adapted cancer cell lines reflect complex evolution in clinical tumors.
bioRxiv 2024:01.20.576412-01.20.576412(2024)

Entry history
Entry creation10-Sep-2024
Last entry update10-Sep-2024
Version number1